Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
Eligible subjects must have a primary diagnosis of MDD without psychotic features based on the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1 ratio to receive either solriamfetol (300 mg) or placebo for 6 weeks.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT
Current major depressive episode
Male or female, aged 18 to 65 inclusive
You may not be if
Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription
Unable to comply with study procedures
Medically inappropriate for study participation in the opinion of the investigator
